Auranofin

DRUG12 trials

Conditions

AmoebiasisAmoebic DysenteryChronic InfectionChronic Lymphocytic Leukemia (CLL)Extensive Stage Small Cell Lung CarcinomaGiardiasisGlioblastomaHIV

Early Phase 1

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

CompletedNCT01747798

Mayo ClinicRecurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer

Start: 2012-11-02End: 2015-04-06Updated: 2019-08-02

Phase 1

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

CompletedNCT01737502

Mayo ClinicExtensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma +5

Start: 2014-05-14End: 2023-04-24Updated: 2025-09-05

Auranofin PK Following Oral Dose Administration

CompletedNCT02089048

National Institute of Allergy and Infectious Diseases (NIAID)Amoebiasis

Start: 2014-04-02End: 2015-05-13Updated: 2017-04-28

Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer

WithdrawnNCT02126527

Mayo ClinicRecurrent Non-small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific

Start: 2013-08-31Updated: 2016-08-26

Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection

WithdrawnNCT02176135

Vaccine and Gene Therapy Institute, FloridaHIV

End: 2017-01-31Updated: 2015-02-26

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

CompletedNCT02770378

University of UlmGlioblastoma

Start: 2016-11-30End: 2020-12-31Updated: 2021-10-05

Phase 2

Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

CompletedNCT01419691

University of Kansas Medical CenterChronic Lymphocytic Leukemia (CLL), Leukemia, Prolymphocytic, Small Lymphocytic Lymphoma

Start: 2011-09-30End: 2015-09-30Updated: 2016-01-18

Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome

CompletedNCT02063698

Mayo ClinicPain

Start: 2014-02-19End: 2016-11-11Updated: 2019-04-23

Auranofin for Giardia Protozoa

CompletedNCT02736968

National Institute of Allergy and Infectious Diseases (NIAID)Amoebic Dysentery, Giardiasis

Start: 2016-11-06End: 2021-03-10Updated: 2023-01-26

Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

TerminatedNCT03456700

Mayo ClinicOvarian Serous Tumor, Recurrent Ovarian Carcinoma

Start: 2018-03-30End: 2019-07-31Updated: 2025-05-08

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

Not yet recruitingNCT06805656

Federal University of São PauloHiv, HIV I Infection

Start: 2025-09-01End: 2027-12-31Target: 70Updated: 2025-08-11

Unknown Phase

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

CompletedNCT02961829

Federal University of São PauloChronic Infection, HIV

Start: 2015-07-31End: 2020-03-31Updated: 2020-07-28

Kompass Onkologie2025-02-20

Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.

2024-02-235 citations

EXTH-72. TTFIELDS ENHANCE THE ANTINEOPLASTIC ACTIVITY OF THE DRUG-REPURPOSING APPROACH CUSP9V3 IN GLIOBLASTOMA IN VITRO

Neuro-Oncology2022-11-011 citations

Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial.

2022-01-127 citations

In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma

Pharmaceuticals2021-11-2921 citations

Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial.

2019-08-0535 citations

Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma

British Journal of Pharmacology2019-06-2131 citations

EXTH-54. Bcl-2/Bcl-xL INHIBITION SYNERGISTICALLY ENHANCES THE ANTI-NEOPLASTIC ACTIVITY OF CUSP9 AGAINST GLIOBLASTOMA CELLS IN VITRO

Neuro-Oncology2018-11-011 citations

EXTH-45. THE REPURPOSED CUSP9 REGIMEN EXERTS POTENT ANTI-NEOPLASTIC ACTIVITY AGAINST GLIOBLASTOMA CELLS IN VITRO

Neuro-Oncology2018-11-01

Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent

Antimicrobial Agents and Chemotherapy2016-11-08142 citations

Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia

Blood2013-11-1511 citations